OM
NBSE

Opaleye Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Opaleye Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-915
Closed -$1.18M – 59
2016
Q1 		$1.18M Buy
+915
New +$1.3M 0.73% 39

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Opaleye Management's NBSE Position: Q2 2016 in Review

Opaleye Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2016, closing a stake of 915 shares — an estimated $1.18M sold.

Opaleye Management first reported a position in NBSE in Q1 2016 and held it in 1 quarter. The position peaked at $1.18M in Q1 2016. 51 funds tracked by Wall St. Rank hold NBSE as of Q2 2016.

  • Opaleye Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Opaleye Management sold 915 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $1.18M.
  • Opaleye Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • Opaleye Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.18M in Q1 2016.
  • 51 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.